How to Cite
Abstract
Introduction. The effectiveness of the Asian regimen of adjuvant chemotherapy in patients with gastric cancer in the European population remains unclear. The aim of our study was a retrospective assessment of adjuvant chemotherapy (XELOX regimen) after radical surgery (R0) on overall survival. Methods. Database of pts with resectable gastric cancer with stage >pT3 and/or pN+ and M0, who were operated (R0) at single oncological institution during 2007-2017 was reviewed. In univariate and multivariate analyzes were included demographic characteristics, type of tumor according to Lauren, stage, type of treatment and others. Results. 396 pts were identified and 286 were available for analysis.106 (37%) pts received at least one cycle of adjuvant chemotherapy. In univariate analysis, 5OS rate was 64% [95% Cl, 52-80] и 56% [95% Cl, 48-64; p=0,21] in patients received adjuvant chemotherapy and only surgical treatment. After stratifying patients depending on the regional lymph nodes metastasis, 5OS rate in pts with pN1-3 was 69% [95% CI, 57-85] vs 47% [95% CI, 39-58; p = 0,01], respectively...References
Davis P.A., Sano Т. The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? // Crit. Rev. Oncol. Hematol. -2001. - Vol. 40. - P 77-94. - DOI: 10.1016/S1040-8428(00)00131-1
Strong V.E., Song K.Y, Park C.H. et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram // Ann. Surg. - 2010. - Vol. 251(4). - P. 640-646. - DOI: 10.1097/SLA.0b013e3181d3d29b
Wang J., Sun Y, Bertagnolli M.M. Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database // Ann. Surg. Oncol. - 2015. - Vol. 22(9). - P 2965-2971. - DOI: 10.1245/s10434-015-4388-4
Cunningham D., Allum W.H., Stenning S.P, Thompson J.N. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer // N. Engl. J. Med. - 2006. - Vol. 355. - P 11-20. - DOI: 10.1056/NEJMoa055531
Ychou M., Boige V., Pignon J-P, Conroy T. et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial // J. Clin. Oncol. - 2011. - Vol. 29(13). - P 1715-1721. - DOI: 10.1200/JC0.2010.33.0597
Al-Batran S.E., Pauligk C., Homann N. et al. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FL0T4 trial (German Gastric Group at AIO) // Ann. Oncol. - 2017. - Vol. 28 (1). - DOI: 10.1093/annonc/mdx302.007
Bang Y.J., Kim Y.W.,Yang H.K. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial // Lancet. - 2012. - Vol. 379(9813). - P 315321. - DOI: 10.1016/S0140-6736(11)61873-4
Sasako M., Sakuramoto S., Katai H. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer // J. Clin. Oncol. - 2011. - Vol. 29(33). - P 4387-4393. - DOI: 10.1200/JCO.2011.36.5908
Noh S.H., Park S.R., Yang H.K. et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (Classic): 5-year follow-up of an open-label, randomised phase 3 trial // Lancet oncol. - 2014. - Vol. 15(12). - P 1389-1396. - DOI: 10.1016/S1470-2045(14)70473-5
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019